Blueprint Medicines Corp Presents Updated EXPLORER Trial Data for Avapritinib in Patients with Systemic Mastocytosis at 24th EHA
שיחת ועידה Blueprint Medicines Corp
Blueprint Medicines Corp Conference call will be held on 17/06/2019. During the earnings conference call's session Blueprint Medicines Corp will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Blueprint Medicines Corp for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
We are a biopharmaceutical company focused on improving the lives of patients with genomically defined diseases driven by abnormal kinase activation. Our approach is to systematically and reproducibly identify kinases that are drivers of diseases in genomically defined patient populations and to craft drug candidates with therapeutic windows that may provide significant and durable clinical responses to patients without adequate treatment options. This integrated biology and chemistry approach enables us to drug known kinases that have been difficult to inhibit selectively and also identify, characterize and drug novel kinase targets. By focusing on diseases in genomically defined patient populations, we believe that we will have a more efficient development path with a greater likelihood of success. Leveraging our novel target discovery engine, we have developed a robust small molecule drug pipeline in cancer and a rare genetic disease.קרא עוד שיחת ועידה